Hereditary Cancer Programs Webinar - Part 1
On October 2, the AACI Physician Clinical Leadership Initiative (PCLI) presented a webinar on models of testing for pancreatic, breast, ovarian, and prostate cancers.

The webinar—the first in a two-part series—was presented by Marie Wood, MD, and Wendy McKinnon, MS. Dr. Wood is the founder and principal investigator of the High Risk Breast Program (HRBP) at the University of Vermont Cancer Center, a professor of medicine at the University of Vermont and The University of Vermont Medical Center, and a medical oncologist at the University of Vermont Cancer Center. McKinnon is a cancer genetics counselor at the University of Vermont Cancer Center and a clinical assistant professor at the Larner College of Medicine, University of Vermont. 

Through case studies and guidelines for high-risk individuals, the presenters shared recommendations for genetic testing in patients and their family members. Indications for genetic testing include cancer type and pathology in patients with cancer, family history, and ethnicity. Males with breast cancer, individuals with metastatic prostate or pancreatic cancer, and individuals of Ashkenazi Jewish heritage are all good candidates for genetic testing, due to their increased risk for certain cancers and the survival benefit afforded by early detection.
Register for Part 2
The second webinar of the series will highlight models of testing for colon and hematologic cancers and informed consent. It will be presented by Joanne Jeter, MD, oncologist and associate professor of medicine, and Heather Hampel, MS, LGC, associate director of the division of human genetics, from The Ohio State University Comprehensive Cancer Center, James Cancer Hospital & Solove Research Institute.

Wednesday, November 13 | 11:00 am ET
Medical Arts Building
3708 Fifth Avenue, Suite 503
Pittsburgh, PA 15213